Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

BACKGROUND: Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI), is active against wild-type Human Immunodeficiency Virus (HIV)-1 and the most common NNRTI-resistant variants, and has a favorable and unique in vitro resistance profile. METHODS: DRIVE-AHEAD is a phase 3,...

Descripción completa

Detalles Bibliográficos
Autores principales: Orkin, Chloe, Squires, Kathleen E, Molina, Jean-Michel, Sax, Paul E, Wong, Wing-Wai, Sussmann, Otto, Kaplan, Richard, Lupinacci, Lisa, Rodgers, Anthony, Xu, Xia, Lin, Gina, Kumar, Sushma, Sklar, Peter, Nguyen, Bach-Yen, Hanna, George J, Hwang, Carey, Martin, Elizabeth A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355823/
https://www.ncbi.nlm.nih.gov/pubmed/30184165
http://dx.doi.org/10.1093/cid/ciy540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355823/
https://www.ncbi.nlm.nih.gov/pubmed/30184165
http://dx.doi.org/10.1093/cid/ciy540

Ejemplares similares